Search research articles
Contact Us
Filters
Showing results (51-60 of 89) with videos related to
Page
of 9
Sort By:
The Lancet. Oncology
|
July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Marina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2010
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
Daniel J Sargent, Silvia Marsoni, Genevieve Monges, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 31, 2002
Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial
Patrizia Olmi, Sergio Crispino, Carlo Fallai, et al.
Cancer Cell
|
December 30, 2022
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
Vito Amodio, Simona Lamba, Rosaria Chilà, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2023
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Giorgio Patelli, Gianluca Mauri, Federica Tosi, et al.
Eclinicalmedicine
|
October 25, 2023
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations
Alberto Giovanni Leone, Raffaella Casolino, Dario Trapani, et al.
The Oncologist
|
April 7, 2019
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi, Alessio Amatu, Luca Porcu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
Nature Medicine
|
August 1, 2022
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 89) with videos related to
Sort By:
Page
of 9
The Lancet. Oncology
|
July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Marina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2010
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
Daniel J Sargent, Silvia Marsoni, Genevieve Monges, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 31, 2002
Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial
Patrizia Olmi, Sergio Crispino, Carlo Fallai, et al.
Cancer Cell
|
December 30, 2022
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
Vito Amodio, Simona Lamba, Rosaria Chilà, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2023
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Giorgio Patelli, Gianluca Mauri, Federica Tosi, et al.
Eclinicalmedicine
|
October 25, 2023
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations
Alberto Giovanni Leone, Raffaella Casolino, Dario Trapani, et al.
The Oncologist
|
April 7, 2019
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi, Alessio Amatu, Luca Porcu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
Nature Medicine
|
August 1, 2022
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
Page
of 9